Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study.

The journal of allergy and clinical immunology. In practice·2020
Same author

Device mechanics and evaluation of inspiratory flow rate required of the beclomethasone dipropionate breath-actuated inhaler.

Allergy and asthma proceedings·2019
Same author

AR101 Oral Immunotherapy for Peanut Allergy.

The New England journal of medicine·2018
Same author

Beclomethasone HFA for the treatment of allergic rhinitis.

Expert opinion on pharmacotherapy·2015
Same author

Re: does omitted history misrepresent OIT role for food allergy today?

The journal of allergy and clinical immunology. In practice·2014
Same author

Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.

The journal of allergy and clinical immunology. In practice·2014

Related Experiment Video

Updated: May 16, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

A valved holding chamber does not decrease the bronchodilator activity of budesonide-formoterol combination metered

Lyndon E Mansfield1, Ruby Maynes

  • 1Western Sky Medical Research, El Paso, TX 79903, USA. immunman@westernskymed.com

The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|November 27, 2012
PubMed
Summary
This summary is machine-generated.

Valved holding chambers (VHCs) do not negatively impact the bronchodilating effects of budesonide/formoterol pressurized metered dose inhalers (pMDIs) in well-trained asthma patients. This indicates VHCs are a safe delivery method for this combination therapy.

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method
08:44

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Published on: February 2, 2024

Related Experiment Videos

Last Updated: May 16, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method
08:44

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Published on: February 2, 2024

Area of Science:

  • Respiratory Medicine
  • Pharmacology
  • Medical Devices

Background:

  • Pressurized metered dose inhalers (pMDIs) require coordinated actuation and inhalation.
  • Valved holding chambers (VHCs) were designed to improve pMDI usability for patients with coordination difficulties.
  • Limited in vivo data exists on VHCs' impact on bronchodilation from combination inhaler therapies.

Purpose of the Study:

  • To evaluate the effect of VHCs on the bronchodilating actions of budesonide/formoterol pMDI.
  • To compare the efficacy of budesonide/formoterol delivered via pMDI with and without a VHC.

Main Methods:

  • A randomized crossover study involving 16 adult asthmatic subjects.
  • Subjects used budesonide/formoterol pMDI with and without a VHC on separate occasions.
  • Spirometry and impedance oscillometry were measured over a 12-hour period.

Main Results:

  • No significant differences in FEV-1, FEV-1/FVC, or resistance were observed between pMDI and VHC methods.
  • Both delivery methods resulted in rapid bronchodilation onset within 3-5 minutes.
  • The area under the curve for FEV-1 was similar across both conditions over 12 hours.

Conclusions:

  • VHCs do not appear to have a deleterious effect on the bronchodilator activity of budesonide/formoterol combination inhalers.
  • Equivalent bronchodilation was achieved with both pMDI and VHC delivery in well-trained asthmatic subjects.
  • Further research is needed to confirm these findings in patients with pMDI coordination issues.